BOULDER, Colo.–(BUSINESS WIRE)–Clovis Oncology, Inc. (NASDAQ:CLVS) today announced that the U.S. Food and Drug Administration (FDA) has approved Rubraca® (rucaparib) tablets for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this …
Original Article: FDA Approves Clovis Oncology’s Rubraca as Maintenance Treatment of Recurrent Ovarian Cancer